StreetInsider.com News Articles

Form 8-K Tarsus Pharmaceuticals, For: Sep 04

Thu, 10 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260910/27048426.html

Tarsus Pharmaceuticals (TARS) PT Raised to $105 at Jefferies

Tue, 08 Sep 2026 13:41:09 -0400

Jefferies analyst Anthony Petrone raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $105.00 (from $88.00) while maintaining a Buy rating.

The analyst comments "TARS stock has rallied post Q2 EPS on a combo of (1) increased Xdemvy 2026 guidance and recent scripts suggest a strong Q3; (2) Alkeus tuck-in for a Phase III-ready rare-disease asset injects new biotech pipeline into the narrative (we est $1B peak); and (3) iRenix deal for another Phase III asset. Valuation at $4B cap remains inexpensive over the long term, given multiple pipeline data-card flips over the next 1-3 years + strong Xdemvy base

Tarsus Pharmaceuticals (TARS) PT Raised to $105 at Jefferies

Tue, 08 Sep 2026 13:41:09 -0400

Jefferies analyst Anthony Petrone raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $105.00 (from $88.00) while maintaining a Buy rating.

Tarsus to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:30:00 -0400

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8^th
H.C. Wainwright 28^th Annual Global Investment Conference on Tuesday, September 15^th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and

Tarsus to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:30:00 -0400

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8^th
H.C. Wainwright 28^th Annual Global Investment Conference on Tuesday, September 15^th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and

Form 144 Tarsus Pharmaceuticals, Filed by: Mottiwala Aziz

Tue, 25 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260825/26975015.html

Form 144 Tarsus Pharmaceuticals, Filed by: Mottiwala Aziz

Tue, 25 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260825/26975015.html

Form 144 Tarsus Pharmaceuticals, Filed by: Mottiwala Aziz

Wed, 19 Aug 2026 14:28:00 -0400

si-local-file:///var/storage/secattach/20260819/26949520.html

Form 144 Tarsus Pharmaceuticals, Filed by: Mottiwala Aziz

Wed, 19 Aug 2026 14:28:00 -0400

si-local-file:///var/storage/secattach/20260819/26949520.html

Form SCHEDULE 13G/A Tarsus Pharmaceuticals, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919265.html

Form SCHEDULE 13G/A Tarsus Pharmaceuticals, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20260813/26919265.html

Tarsus Pharmaceuticals (TARS) PT Raised to $100 at Oppenheimer

Wed, 12 Aug 2026 07:51:21 -0400

Oppenheimer analyst Mazahir Alimohamed raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $100.00 (from $97.00) while maintaining a Outperform rating.

Tarsus Pharmaceuticals (TARS) PT Raised to $100 at Mizuho

Mon, 10 Aug 2026 07:13:46 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $100.00 (from $98.00) while maintaining a Outperform rating.

Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 21c

Thu, 06 Aug 2026 08:27:18 -0400

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.43), $0.21 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $173.91 million versus the consensus estimate of $167.33 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

Form 10-Q Tarsus Pharmaceuticals, For: Jun 30

Thu, 06 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260806/26878748.html

Form 10-Q Tarsus Pharmaceuticals, For: Jun 30

Thu, 06 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260806/26878748.html

Form 8-K Tarsus Pharmaceuticals, For: Aug 06

Thu, 06 Aug 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260806/26878732.html

Form 8-K Tarsus Pharmaceuticals, For: Aug 06

Thu, 06 Aug 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260806/26878732.html

Form 8-K Tarsus Pharmaceuticals, For: Aug 05

Thu, 06 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26878614.html

Form 8-K Tarsus Pharmaceuticals, For: Aug 05

Thu, 06 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26878614.html

Form 8-K Tarsus Pharmaceuticals, For: Jul 31

Thu, 06 Aug 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26878570.html

Form 8-K Tarsus Pharmaceuticals, For: Jul 31

Thu, 06 Aug 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26878570.html

Tarsus Pharmaceuticals posts 69% sales jump, raises 2026 guidance

Thu, 06 Aug 2026 07:06:06 -0400

Tarsus Pharmaceuticals (NASDAQ: TARS) reported second quarter 2026 net product sales of $173.9 million for its eye drop XDEMVY, a 69% increase from $102.7 million in the same period of 2025, according to a company press release.

The Irvine, California-based company raised its full-year 2026 XDEMVY net product sales guidance to $685–$705 million. The drug treats Demodex blepharitis, an eyelid condition caused by mite infestation.

The company reported a net loss of $18.6 million for the quarter, or $(0.43) per share, compared with a net loss of $20.3 million, or $(0.48) per share, in the second quarter of 2025. Selling, general and

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Thu, 06 Aug 2026 07:03:00 -0400

Generated second quarter 2026 XDEMVY^® net product sales of $173.9 million, an increase of more than 69% year-over-year

Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million

Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3 clinical program for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States that can lead to blindness

Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors

Management to host conference call today,

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Thu, 06 Aug 2026 07:03:00 -0400

Generated second quarter 2026 XDEMVY^® net product sales of $173.9 million, an increase of more than 69% year-over-year

Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million

Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3 clinical program for Stargardt disease, an inherited retinal disease affecting more than 36,000 patients in the United States that can lead to blindness

Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors

Management to host conference call today,